According to a research note from UBS Investment Research, despite expected short-term gains Unilever faces a number of significant challenges that it must overcome on the road to recovery.
According to UBS analyst Alan Erskine, Unilever’s second quarter sales are likely to grow 3.3% to EUR10.25bn (US$12.88bn). “In Q2 we anticipate organic sales growth of 3.6% (3.1% volume/mix), driven largely by another strong performance in the emerging markets,” the note stated.
Shares of the Netherlands-based company have dropped by 9% in value since it reported weak first quarter results in May. The share has “fallen to a level where we consider them to be slightly oversold,” Erskine observed.
However, the research note continued: “we remain sceptical of any meaningful recovery”.
Erskine said that Unilever’s poor performance is the result of corporate culture issues. “We believe the causes of Unilever’s marketplace underperformance have a lot to do with corporate culture and may not be easily addressed,” he commented.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMoreover, UBS warned of increasing competition from Procter & Gamble.
UBS maintained a “neutral” rating and a price target of US$24.03.
Unilever is scheduled to report second-quarter 2006 results on 3 August.